ArticleResearch in pharmaceutical sciences2021
QSAR analysis of pyrimidine derivatives as VEGFR-2 receptor inhibitors to inhibit cancer using multiple linear regression and artificial neural network.
Article in Research in pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Current Computational Approaches for the Discovery of Novel Anticancer Agents Targeting VEGFR and SIRT Signaling Pathways.Pharmaceutics · 2026Review
- QSAR analysis of VEGFR-2 inhibitors based on machine learning, Topomer CoMFA and molecule docking.BMC chemistry · 2024Article
- Application of Support Vector Machine Classification Model to Identification of Vascular Endothelial Growth Factor Receptor Inhibitors.Advanced biomedical research · 2024Article
- Identification of new small molecules as dual FoxM1 and Hsp70 inhibitors using computational methods.Research in pharmaceutical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIn this study, the pharmacological activity of 33 compounds of furopyrimidine and thienopyrimidine as vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors to inhibit cancer was investigated. The most important angiogenesis inducer is VEGF endothelial growth factor, which exerts its activity by binding to two tyrosine kinase receptors called VEGFR-1 and VEGFR-2. Due to the critical role of VEGF in the pathological angiogenesis of this molecule, it is a valuable therapeutic target for anti-angiogenesis therapies. EXPERIMENTAL APPROACH: After calculating descriptors using SPSS software and stepwise selection method, 5 descriptors were used for modeling in multiple linear regression (MLR) and artificial neural network (ANN). The calibration series and the test series in this study included 26 and 7 combinations, respectively. FINDINGS/
resultsThe performance evaluation of models was determined by the R CONCLUSION AND IMPLICATIONS: The results were evaluated by different statistical methods and it was concluded that the nonlinear neural network method is powerful to predict the pharmacological activity of similar compounds, and because of the complex and nonlinear relationships, the MLR was not capable of establishing a good model with high predictive power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.